Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00008008 · ClinicalTrials.gov registry record · Phase 2
Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma
A Phase 2 study, sponsored by Herbert Irving Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00008008 is a Phase 2 study that has completed, run by Herbert Irving Comprehensive Cancer Center. The registered enrollment target is 40 participants.
The verdict
NCT00008008, a Phase 2 study, has completed, sponsored by Herbert Irving Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This phase II trial is studying how well thiotepa followed by peripheral stem cell or bone marrow transplant works in treating patients with malignant glioma.
Interventions
- DRUG cyclophosphamide
- BIOLOGICAL filgrastim
- DRUG thiotepa
- BIOLOGICAL sargramostim
- PROCEDURE autologous bone marrow transplantation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1997-09 |
| Est. Completion | 2008-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00008008
The ClinicalTrials.gov registry entry for NCT00008008 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Herbert Irving Comprehensive Cancer Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00008008 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00008008 about?
NCT00008008 is a clinical study titled "Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma". RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy with peripheral stem cell or bone marrow transplant may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Thi...
What is the current status of trial NCT00008008?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 1997-09. Estimated completion is 2008-05.
What interventions are being tested in trial NCT00008008?
The interventions under investigation include: cyclophosphamide (DRUG), filgrastim (BIOLOGICAL), thiotepa (DRUG), sargramostim (BIOLOGICAL), autologous bone marrow transplantation (PROCEDURE).
Who is sponsoring clinical trial NCT00008008?
This trial is sponsored by Herbert Irving Comprehensive Cancer Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.